Reviving the guardian of the genome: Small molecule activators of p53
Open accessThe DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Abstract
&NA; The tumor suppressor p53 is one of the most important proteins for protection of genomic stability and cancer prevention. Cancers often inactivate it by either mutating its gene or disabling its function. Thus, activating p53 becomes an attractive approach for the development of molecule‐based anti‐cancer therapy. The past decade and half have witnessed tremendous progress in this area. This essay offers readers with a grand review on this progress with updated information about small molecule activators of p53 either still at bench work or in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312
Blinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163 · cited 1×
“Apoptosis is achieved through transcriptional activation of subsets of apoptotic genes, of which is dependent on the source and duration of offending stressors (Vousden & Prives, 2009).”
BackgroundATM and related protein kinases: safeguarding genome integrity
Shiloh, Y. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1011 · Cited by 2,577 · cited 2×
“For example, DNA damage triggers the activation of kinases such as Chk1/Chk2 (Shieh, Ahn, Tamai, Taya, & Prives, nome: Small molecule activators of p53, Pharmacology & Therapeutics 2000) and ATM/ATR (Shiloh, 2003), which phosphorylate sites on p53's N-terminus, lowering its affinity for MDM2/MDMX. Alternatively, activ…”
BackgroundCrystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551 · cited 1×
“residues, of which four (Cys182, Cys229, Cys242, and Cys277) are exposed on the surface in wild-type conformation (Cho et al., 1994).”
BackgroundSenescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · cited 1×
“…cancers and harness its ability to induce cell cycle arrest, senescence, and apoptosis (Martins, Brown-Swigart, & Evan, 2006; Ventura et al., 2007; Xue et al., 2007). p53 activators can generally be grouped into two broad categories depending on the mechanism of action: molecules that activate…”
BackgroundRyan, D. P., Hong, T. S., & Bardeesy, N. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1404198 · Cited by 2,348
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206 · cited 1×
“X-ray crystallography demonstrated precise binding of a peptide region in p53's N-terminal transactivating domain, specifically residues Phe19, Trp23, and Leu26, to a hydrophobic cleft within MDM2's own N-terminal domain, suggesting that this site may be suitable for targeting (Kussie et al., 1996).”
BackgroundNegative Control of p53 by Sir2α Promotes Cell Survival under Stress
Luo, J., Nikolaev, A. Y., Imai, S.-I., Chen, D., Su, F., Shiloh, A., Guarente, L., & Gu, W. (2001) · Cell · doi:10.1016/s0092-8674(01)00524-4 · Cited by 2,081
The first 30 years of p53: growing ever more complex.
Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967 · cited 1×
“…Liao, Liao, & Lu, 2012) ismatched by its equally impressive array of protective capabilities, including induction of cell cycle arrest, apoptosis, cellular senescence, DNA repair, and inhibition of angiogenesis and metastasis (Bieging & Attardi, 2012; Levine & Oren, 2009; Sengupta & Harris, 2005).”
BackgroundOncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
Honda, R., Tanaka, H., & Yasuda, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01480-4 · Cited by 1,951
Transcriptional control of human p53-regulated genes
Riley, T., Sontag, E., Chen, P., & Levine, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2395 · Cited by 1,921
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · cited 1×
“…p53 pathway in human cancers and harness its ability to induce cell cycle arrest, senescence, and apoptosis (Martins, Brown-Swigart, & Evan, 2006; Ventura et al., 2007; Xue et al., 2007). p53 activators can generally be grouped into two broad categories depending on the mechanism of action:…”
BackgroundThe p53-mdm-2 autoregulatory feedback loop.
Wu, X., Bayle, J. H., Olson, D., & Levine, A. J. (1993) · Genes & Development · doi:10.1101/gad.7.7a.1126 · Cited by 1,801
Kruse, J.-P., & Gu, W. (2009) · Cell · doi:10.1016/j.cell.2009.04.050 · Cited by 1,610 · cited 2×
“Classically, activation of p53 occurs when interaction between p53 and MDM2/MDMX is perturbed, with different stressors having different mechanisms of disruption (Kruse & Gu, 2009).”
BackgroundPetitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545 · cited 1×
“…p53 family members p63 and p73, deregulation ofmetabolic pathways, augmented metastasis and angiogenesis, resistance to chemotherapy, altered epigenetic modifications, and proteasome machinery subversion (Haupt, Raghu, & Haupt, 2016; Muller & Vousden, 2014; Walerych et al., 2016; Zhu et al., 2015).”
BackgroundCeritinib in ALK -Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Kim, D.-W., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311107 · Cited by 1,495 · cited 1×
“…and as part of a personalized neuroblastoma clinical trial that will apply next generation sequencing on biopsies of patient tumors, followed by treatment with either trametinib, certinib (an ALK inhibitor) (Shaw et al., 2014), or HDM201, depending on the deep sequencing results (NCT02780128).”
BackgroundRescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420
DRAM, a p53-Induced Modulator of Autophagy, Is Critical for Apoptosis
Crighton, D., Wilkinson, S., O'Prey, J., Syed, N., Smith, P., Harrison, P. R., Gasco, M., Garrone, O., Crook, T., & Ryan, K. M. (2006) · Cell · doi:10.1016/j.cell.2006.05.034 · Cited by 1,380 · cited 1×
“In addition, activation of autophagy regulator DRAM1may also play a role in apoptosis (Crighton et al., 2006). p53 can also function outside of the nucleus to directly inhibit antiapoptotic proteins Bcl-2 and Bcl-XL, an example of p53 transcription-independent activity (Green & Kroemer, 2009;…”
BackgroundRegulating the p53 pathway: in vitro hypotheses, in vivo veritas
Toledo, F., & Wahl, G. M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc2012 · Cited by 1,286
Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53
Jones, S. N., Roe, A. E., Donehower, L. A., & Bradley, A. (1995) · Nature · doi:10.1038/378206a0 · Cited by 1,280
Cytoplasmic functions of the tumour suppressor p53
Green, D. R., & Kroemer, G. (2009) · Nature · doi:10.1038/nature07986 · Cited by 1,106 · cited 1×
“…function outside of the nucleus to directly inhibit antiapoptotic proteins Bcl-2 and Bcl-XL, an example of p53 transcription-independent activity (Green & Kroemer, 2009; Murphy, Leu, & George, 2004). p53's indispensable role in maintaining genome-wide stability has led biologists to christen it…”
BackgroundRestoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067
Shieh, S.-Y., Ahn, J., Tamai, K., Taya, Y., & Prives, C. (2000) · Genes & Development · doi:10.1101/gad.14.3.289 · Cited by 972
TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes
Petitjean, A., Achatz, M. I. W., Borresen-Dale, A. L., Hainaut, P., & Olivier, M. (2007) · Oncogene · doi:10.1038/sj.onc.1210302 · Cited by 884
Awakening guardian angels: drugging the p53 pathway
Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881
Inhibiting the p53–MDM2 interaction: an important target for cancer therapy
Chène, P. (2003) · Nature Reviews Cancer · doi:10.1038/nrc991 · Cited by 765 · cited 1×
“The first wild-type p53 activators were devised using a target based approach directed against MDM2-p53 interaction, as several lines of studies have validated MDM2 as an oncotarget (Chene, 2003).”
MethodAcetylation of the p53 DNA-binding domain regulates apoptosis induction.
Sykes, S. M., Mellert, H. S., Holbert, M. A., Li, K., Marmorstein, R., Lane, W. S., & McMahon, S. B. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.11.026 · Cited by 752 · cited 1×
“Acetylation of p53 is indispensible for its activation and is correlated with augmented site-specific DNA binding (Luo et al., 2004), particularly for genes associated with induction of apoptosis (Sykes et al., 2006).”
BackgroundDing, K., Lu, Y., Nikolovska-Coleska, Z., Wang, G., Qiu, S., Shangary, S., Gao, W., Qin, D., Stuckey, J., Krajewski, K., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051122a · Cited by 702 · cited 2×
“…hydantoin Dual MDM2/MDMX antagonist (Graves et al., 2012) (Graves et al., 2012) MI-219 MI-888 MI-773 (SAR405838) Spiro-oxindole MDM2:p53 antagonist (Ding et al., 2006; Shangary et al., 2008) (Zhao, Yu, et al., 2013) (Jung et al., 2016; Wang et al., 2014) Methylbenzo-amines Methylbenzo-amine…”
BackgroundShangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708917105 · Cited by 660 · cited 2×
“They discovered that the spiro-oxindole MI-219 binds to MDM2 by mirroring its interaction with p53 at residues Phe19, Trp23, and Leu26 within its hydrophobic cleft in amanner similar to theNutlin compounds, exceptwith substantially higher affinity (Shangary et al., 2008; Zhao, Liu, et al., 2013).”
BackgroundMDMX: a novel p53‐binding protein with some functional properties of MDM2.
Shvarts, A., Steegenga, W. T., Riteco, N., van Laar, T., Dekker, P., Bazuine, M., van Ham, R. C., van der Houven van Oordt, W., Hateboer, G., van der Eb, A. J., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00919.x · Cited by 648
Modeling the Therapeutic Efficacy of p53 Restoration in Tumors
Martins, C. P., Brown-Swigart, L., & Evan, G. I. (2006) · Cell · doi:10.1016/j.cell.2006.12.007 · Cited by 600
Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
Ding, Q., Zhang, Z., Liu, J.-J., Jiang, N., Zhang, J., Ross, T. M., Chu, X.-J., Bartkovitz, D., Podlaski, F., Janson, C., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400487c · Cited by 595 · cited 2×
“Continued efforts and support from Hoffmann-La Roche led to the discovery of an even more potent and selective MDM2:p53 inhibitor, the pyrrolidine-based molecule RG7388 (also known as RO5503781), which would later be named idasanutlin (Ding et al., 2013).”
BackgroundInactivation of the p53 pathway in retinoblastoma
Laurie, N. A., Donovan, S. L., Shih, C.-S., Zhang, J., Mills, N., Fuller, C., Teunisse, A., Lam, S., Ramos, Y., Mohan, A., et al. (2006) · Nature · doi:10.1038/nature05194 · Cited by 595
PRIMA-1 reactivates mutant p53 by covalent binding to the core domain
Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592
Signaling to p53: ribosomal proteins find their way
Zhang, Y., & Lu, H. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.09.024 · Cited by 591 · cited 2×
“…binding, in a similar fashion to p14ARF, protects p53 fromMDM2-mediated degradation (Bhat, Itahana, Jin, & Zhang, 2004; Dai & Lu, 2004; Dai et al., 2004; Jin, Itahana, O'Keefe, & Zhang, 2004; Lindstrom, Deisenroth, & Zhang, 2007; Lohrum, Ludwig, Kubbutat, Hanlon, & Vousden, 2003; Zhang & Lu, 2009).”
BackgroundSelf-citationRay-Coquard, I., Blay, J.-Y., Italiano, A., Le Cesne, A., Penel, N., Zhi, J., Heil, F., Rueger, R., Graves, B., Ding, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70474-6 · Cited by 571 · cited 2×
“RG7112 has completed phase I trials as a standalone drug for advanced solid tumors (NCT00559533), liposarcomas (Ray-Coquard et al., 2012) (NCT01143740), and hematological neoplasms (NCT00623870), as well as phase I trials in combination with doxorubicin in soft tissue sarcomas (NCT01605526) and…”
BackgroundParant, J., Chavez-Reyes, A., Little, N. A., Yan, W., Reinke, V., Jochemsen, A. G., & Lozano, G. (2001) · Nature Genetics · doi:10.1038/ng714 · Cited by 517 · cited 1×
“…are embryonically nonviable as a direct result of unrestricted p53 activation, as evidenced by rescue of this lethal phenotypewhen thesemice are introduced to an additional p53 knockout (Jones, Roe, Donehower, & Bradley, 1995; Montes de Oca Luna, Wagner, & Lozano, G., 1995; Parant et al., 2001).”
BackgroundAcetylation of p53 inhibits its ubiquitination by Mdm2
Li, M., Luo, J., Brooks, C. L., & Gu, W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200578200 · Cited by 503
The pediatric preclinical testing program: Description of models and early testing results
Houghton, P. J., Morton, C. L., Tucker, C., Payne, D., Favours, E., Cole, C., Gorlick, R., Kolb, E. A., Zhang, W., Lock, R., et al. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21078 · Cited by 480
Structural Basis of DNA Recognition by p53 Tetramers
Kitayner, M., Rozenberg, H., Kessler, N., Rabinovich, D., Shaulov, L., Haran, T. E., & Shakked, Z. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.05.015 · Cited by 408
Discovery of RG7112: a small-molecule MDM2 inhibitor in clinical development
Vu, B., Wovkulich, P., Pizzolato, G., Lovey, A., Ding, Q., Jiang, N., Liu, J.-J., Zhao, C., Glenn, K., Wen, Y., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml4000657 · Cited by 395 · cited 2×
“…RG7112 (RO5045337) Imidazolines MDM2:p53 antagonist (Vassilev et al., 2004) (Andreeff et al., 2016; Ray-Coquard et al., 2012; Tovar et al., 2013; Vu et al., 2013) RG7388 (RO5503781/idasanutlin) Pyrrolidine MDM2:p53 antagonist (Chen et al., 2015; Ding et al., 2013; Lakoma et al., 2015; Phelps et…”
BackgroundDesign of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo
Böttger, A., Böttger, V., Sparks, A., Liu, W.-L., Howard, S. F., & Lane, D. P. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00374-5 · Cited by 363 · cited 1×
“Indeed, designed peptides have been shown capable of binding this hydrophobic region with higher affinity than p53 and induce an accumulation of p53 protein and activity, further implicating that this interaction may be druggable (Bottger et al., 1997; Chene et al., 2000).”
BackgroundKeeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4
Marine, J.-C., Francoz, S., Maetens, M., Wahl, G., Toledo, F., & Lozano, G. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401912 · Cited by 352 · cited 1×
“MDMX, also known asMDM4 (HDMX/HDM4 for its human analog), is structurally homologous to MDM2 and can both directly bind to and inhibit p53 as well as stabilize MDM2 to potentiate MDM2's ubiquitination capabilities (Gu et al., 2002; Marine et al., 2006; Shvarts et al., 1996).”
BackgroundResults of the Phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia
Andreeff, M., Kelly, K. R., Yee, K., Assouline, S., Strair, R., Popplewell, L., Bowen, D., Martinelli, G., Drummond, M. W., Vyas, P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0481 · Cited by 352
Wang, S., Sun, W., Zhao, Y., McEachern, D., Meaux, I., Barrière, C., Stuckey, J. A., Meagher, J. L., Bai, L., Liu, L., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0799 · Cited by 328
MDM4 is a key therapeutic target in cutaneous melanoma
Gembarska, A., Luciani, F., Fedele, C., Russell, E. A., Dewaele, M., Villar, S., Zwolinska, A., Haupt, S., de Lange, J., Yip, D., et al. (2012) · Nature Medicine · doi:10.1038/nm.2863 · Cited by 327 · cited 2×
“…et al., Reviving the guardian of the ge (2017), http://dx.doi.org/10.1016/j.pharmthera.2017.03.013 tumor progression in cancers such as melanomas (Gembarska et al., 2012), retinoblastomas (Laurie et al., 2006), and breast carcinomas (Danovi et al., 2004) that highly express MDMX. SJ-172550, an…”
BackgroundInfluentialOncogenic protein interfaces: small molecules, big challenges
Nero, T. L., Morton, C. J., Holien, J. K., Wielens, J., & Parker, M. W. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3690 · Cited by 312
Danovi, D., Meulmeester, E., Pasini, D., Migliorini, D., Capra, M., Frenk, R., de Graaf, P., Francoz, S., Gasparini, P., Gobbi, A., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.13.5835-5843.2004 · Cited by 310 · cited 2×
“…is found in a variety of human cancers, including breast cancer, lung cancer, soft tissue sarcoma, osteosarcoma, bladder cancer, esophageal cancer, and retinoblastoma (Burgess et al., 2016; Danovi et al., 2004; Gembarska et al., 2012; Laurie et al., 2006; Leach et al., 1993; Ramos et al., 2001).”
BackgroundSun, D., Li, Z., Rew, Y., Gribble, M., Bartberger, M. D., Beck, H. P., Canon, J., Chen, A., Chen, X., Chow, D., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401753e · Cited by 290 · cited 2×
“…et al., 2014) AM-8553 AM-7209 AMG 232 Piperidonone MDM2:p53 antagonist (Gonzalez-Lopez de Turiso et al., 2013; Rew et al., 2012; Rew et al., 2014; Sun et al., 2014) AM-8735 Morpholinones (Gonzalez, Eksterowicz, et al., 2014) NVP-CGM097 Dihydro-isoquinolinone MDM2:p53 antagonist (Holzer et al.,…”
BackgroundTovar, C., Graves, B., Packman, K., Filipovic, Z., Xia, B. H. M., Tardell, C., Garrido, R., Lee, E., Kolinsky, K., To, K.-H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2807 · Cited by 283 · cited 2×
“…Reference Nutlin-3a RG7112 (RO5045337) Imidazolines MDM2:p53 antagonist (Vassilev et al., 2004) (Andreeff et al., 2016; Ray-Coquard et al., 2012; Tovar et al., 2013; Vu et al., 2013) RG7388 (RO5503781/idasanutlin) Pyrrolidine MDM2:p53 antagonist (Chen et al., 2015; Ding et al., 2013; Lakoma et…”
BackgroundPRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis
Bykov, V. J. N., Zache, N., Stridh, H., Westman, J., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Oncogene · doi:10.1038/sj.onc.1208419 · Cited by 252 · cited 16×
“The most promising small molecule mutant reactivator to date and the only one of this kind to advance to clinical trials is APR-246 (also known as PRIMA-1MET), as APR-246 has completed a phase I trial for refractory hematologic prostate cancer (NCT00900614) and is currently recruiting for a study examining its efficac…”
BackgroundInfluentialWalerych, D., Lisek, K., Sommaggio, R., Piazza, S., Ciani, Y., Dalla, E., Rajkowska, K., Gaweda-Walerych, K., Ingallina, E., Tonelli, C., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3380 · Cited by 239 · cited 1×
“…p53 family members p63 and p73, deregulation ofmetabolic pathways, augmented metastasis and angiogenesis, resistance to chemotherapy, altered epigenetic modifications, and proteasome machinery subversion (Haupt, Raghu, & Haupt, 2016; Muller & Vousden, 2014; Walerych et al., 2016; Zhu et al., 2015).”
BackgroundActivation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization
Graves, B., Thompson, T., Xia, M., Janson, C., Lukacs, C., Deo, D., Di Lello, P., Fry, D., Garvie, C., Huang, K.-S., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203789109 · Cited by 230
Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells
Abraham, S. A., Hopcroft, L. E. M., Carrick, E., Drotar, M. E., Dunn, K., Williamson, A. J. K., Korfi, K., Baquero, P., Park, L. E., Scott, M. T., et al. (2016) · Nature · doi:10.1038/nature18288 · Cited by 225
Tumor suppression and normal aging in mice with constitutively high p53 activity
Mendrysa, S. M., O'Leary, K. A., McElwee, M. K., Michalowski, J., Eisenman, R. N., Powell, D. A., & Perry, M. E. (2006) · Genes & Development · doi:10.1101/gad.1378506 · Cited by 210
Holzer, P., Masuya, K., Furet, P., Kallen, J., Valat-Stachyra, T., Ferretti, S., Berghausen, J., Bouisset-Leonard, M., Buschmann, N., Pissot-Soldermann, C., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00810 · Cited by 203 · cited 2×
“…derivative called NVP-CGM097, which, in addition to in vitro efficacy studies for AML and uveal melanoma, is currently undergoing phase I clinical trials in patients with selected advanced solid tumors (Carita et al., 2016; Holzer et al., 2015; Weisberg et al., 2015) (NCT01760525).”
BackgroundIdentification and Characterization of the First Small Molecule Inhibitor of MDMX
Reed, D., Shen, Y., Shelat, A. A., Arnold, L. A., Ferreira, A. M., Zhu, F., Mills, N., Smithson, D. C., Regni, C. A., Bashford, D., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.056747 · Cited by 198 · cited 2×
“…2012; Yang et al., 2005) SP-141 Pyirdo[b]indole MDM2 degradation (Wang et al., 2014) SJ-172550 imidazoline MDMX:p53 antagonist (Bista et al., 2012; Reed et al., 2010) XI-006 (NSC207895) Benzofuroxan MDMX:p53 antagonist (Pishas et al., 2015; H. Wang et al., 2011) XI-011 (NSC146109) Pseudourea…”
BackgroundChelators at the cancer coalface: Desferrioxamine to Triapine and beyond
Yu, Y., Wong, J., Lovejoy, D. B., Kalinowski, D. S., & Richardson, D. R. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1954 · Cited by 195
Deconstructing p53 transcriptional networks in tumor suppression
Bieging, K. T., & Attardi, L. D. (2012) · Trends in Cell Biology · doi:10.1016/j.tcb.2011.10.006 · Cited by 194 · cited 1×
“…Liao, Liao, & Lu, 2012) ismatched by its equally impressive array of protective capabilities, including induction of cell cycle arrest, apoptosis, cellular senescence, DNA repair, and inhibition of angiogenesis and metastasis (Bieging & Attardi, 2012; Levine & Oren, 2009; Sengupta & Harris, 2005).”
BackgroundAPR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
Mohell, N., Alfredsson, J., Fransson, Å., Uustalu, M., Byström, S., Gullbo, J., Hallberg, A., Bykov, V. J. N., Björklund, U., & Wiman, K. G. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.143 · Cited by 183 · cited 2×
“Because glutathione has been implicated in resistance to platinum-containing chemotherapeutic reagents (Amable, 2016), APR-246 can mitigate this resistance and indeed shows synergy not only with cisplatin, but also 5-fluorouracil and doxorubicin (Fransson et al., 2016; Mohell et al., 2015).”
BackgroundSolution structure of p53 core domain: Structural basis for its instability
Cañadillas, J. M. P., Tidow, H., Freund, S. M. V., Rutherford, T. J., Ang, H. C., & Fersht, A. R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510941103 · Cited by 174 · cited 1×
“…temperatures, as p53 has a melting temperature of 44 °C and a half-life of only 9 min, shorter than its paralogs p63 and p73 (Bullock et al., 1997; Canadillas et al., 2006). p53 is also kinetically unstable, as the central domain cycles between folded, unfolded, and aggregate states at 37 °C…”
BackgroundPeng, X., Zhang, M.-Q.-Z., Conserva, F., Hosny, G., Selivanova, G., Bykov, V. J. N., Arnér, E. S. J., & Wiman, K. G. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.417 · Cited by 170
PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance
Tessoulin, B., Descamps, G., Moreau, P., Maïga, S., Lodé, L., Godon, C., Marionneau-Lambot, S., Oullier, T., Le Gouill, S., Amiot, M., et al. (2014) · Blood · doi:10.1182/blood-2014-01-548800 · Cited by 166
p53 accumulates but is functionally impaired when DNA synthesis is blocked
Gottifredi, V., Shieh, S.-Y., Taya, Y., & Prives, C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.3.1036 · Cited by 147 · cited 1×
“…targets or have mechanisms of action that may be associated with general toxicity, such as DNA intercalation (Gottifredi, Shieh, Taya, & Prives, 2001), inhibition of ribosomal RNA synthesis (Choong, Yang, Lee, & Lane, 2009; Gottifredi et al., 2001), and disruption ofmitosis (Staples et al., 2008).”
BackgroundImmunological off-target effects of imatinib
Zitvogel, L., Rusakiewicz, S., Routy, B., Ayyoub, M., & Kroemer, G. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.41 · Cited by 142
Zhuang, C., Miao, Z., Zhu, L., Dong, G., Guo, Z., Wang, S., Zhang, Y., Wu, Y., Yao, J., Sheng, C., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300969t · Cited by 131 · cited 2×
“…Zhuang et al., 2011), which all demonstrate nanomolar binding affinities to MDM2 and with one pyrrolidinone exhibiting dual MDM2/MDMX activity (Zhuang et al., 2012) and one pyrrolopyrazole seemingly active against both MDM2 and the NF-κB complex (Zhuang et al., 2014), a different…”
BackgroundAcquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3
Aziz, M. H., Shen, H., & Maki, C. G. (2011) · Oncogene · doi:10.1038/onc.2011.185 · Cited by 131
Kessler, J., Hahnel, A., Wichmann, H., Rot, S., Kappler, M., Bache, M., & Vordermark, D. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-605 · Cited by 103 · cited 2×
“…small molecule chetomin (CTM) is a fungal dithiodiketopiperazine metabolite that has already displayed antitumor effects via inhibition of HIF-1α (Kessler et al., 2010; Viziteu et al., 2016) was recently shown to reactivate the R175Hmutant by binding to the chaperone protein Hsp40 (heat shock…”
BackgroundReis, B., Jukofsky, L., Chen, G., Martinelli, G., Zhong, H., So, W. V., Dickinson, M. J., Drummond, M., Assouline, S., Hashemyan, M., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.139717 · Cited by 91 · cited 2×
“RG7338 has completed phase I clinical trials for AML as a single agent or in combination with cytarabine (NCT01773408) and advanced malignancies (NCT01462175), with one report correlating patient response to MDM2 protein expression (Reis et al., 2016).”
BackgroundA distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097
Jeay, S., Gaulis, S., Ferretti, S., Bitter, H., Ito, M., Valat, T., Murakami, M., Ruetz, S., Guthy, D. A., Rynn, C., et al. (2015) · eLife · doi:10.7554/elife.06498 · Cited by 85 · cited 2×
“…data with genomic data from the ongoing trial has identified distinct p53 target genes that predict sensitivity to NVP-CGM097, a genetic signature that can be used for selection of patients thatwould bemost sensitive to treatmentwith NVP-CGM097 or otherMDM2 antagonists (Jeay et al., 2015).”
BackgroundRational Design and Binding Mode Duality of MDM2–p53 Inhibitors
Gonzalez-Lopez de Turiso, F., Sun, D., Rew, Y., Bartberger, M. D., Beck, H. P., Canon, J., Chen, A., Chow, D., Correll, T. L., Huang, X., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400293z · Cited by 82 · cited 2×
“…Pyrrolopyrazole Dual MDM2/NF-κB antagonist (Zhuang et al., 2014) AM-8553 AM-7209 AMG 232 Piperidonone MDM2:p53 antagonist (Gonzalez-Lopez de Turiso et al., 2013; Rew et al., 2012; Rew et al., 2014; Sun et al., 2014) AM-8735 Morpholinones (Gonzalez, Eksterowicz, et al., 2014) NVP-CGM097…”
BackgroundHiraki, M., Hwang, S.-Y., Cao, S., Ramadhar, T. R., Byun, S., Yoon, K. W., Lee, J. H., Chu, K., Gurkar, A. U., Kolev, V., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.07.016 · Cited by 81
Furet, P., Masuya, K., Kallen, J., Stachyra-Valat, T., Ruetz, S., Guagnano, V., Holzer, P., Mah, R., Stutz, S., Vaupel, A., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.08.010 · Cited by 80
Kojima, K., Burks, J. K., Arts, J., & Andreeff, M. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0337 · Cited by 78 · cited 1×
“…(Zhang, Chu, et al., 2014; Zhang, Ding, et al., 2014) JNJ-26854165 Tryptamine Inhibits MDM2:p53 proteasome interaction (Chargari et al., 2011; Kojima et al., 2010; Patel & Player, 2008; Tabernero et al., 2011) HLI98 5-Deazaflavin Inhibits MDM2 ubiquitin ligase activity (Dickens et al., 2013;…”
BackgroundMdm2 affects genome stability independent of p53
Bouska, A., & Eischen, C. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3732 · Cited by 71 · cited 1×
“…itself may be an attractive option in cancers that overexpress MDM2, as MDM2 has been shown to have oncogenic functions independent of p53, such as inhibition of apoptosis (Gu et al., 2009) and regulation DNA replication (Vlatkovic et al., 2000) and global genome stability (Bouska & Eischen, 2009).”
BackgroundFransson, Å., Glaessgen, D., Alfredsson, J., Wiman, K. G., Bajalica-Lagercrantz, S., & Mohell, N. (2016) · Journal of Ovarian Research · doi:10.1186/s13048-016-0239-6 · Cited by 65
Tabernero, J., Dirix, L., Schöffski, P., Cervantes, A., Lopez-Martin, J. A., Capdevila, J., van Beijsterveldt, L., Platero, S., Hall, B., Yuan, Z., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1101 · Cited by 64
Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy
Zhang, Z., Ding, Q., Liu, J.-J., Zhang, J., Jiang, N., Chu, X.-J., Bartkovitz, D., Luk, K.-C., Janson, C., Tovar, C., et al. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.05.072 · Cited by 60
On the Mechanism of Action of SJ-172550 in Inhibiting the Interaction of MDM4 and p53
Bista, M., Smithson, D., Pecak, A., Salinas, G., Pustelny, K., Min, J., Pirog, A., Finch, K., Zdzalik, M., Waddell, B., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037518 · Cited by 58 · cited 4×
“Both XI-006 and XI-011 induced apoptosis in breast cancer cells and, similar to SJ-172550, synergized with Nutlin in an MDMX and MDM2 dependent manner.”
BackgroundInfluentialRavandi, F., Gojo, I., Patnaik, M. M., Minden, M. D., Kantarjian, H., Johnson-Levonas, A. O., Fancourt, C., Lam, R., Jones, M. B., Knox, C. D., et al. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.07.004 · Cited by 57
Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097
Weisberg, E., Halilovic, E., Cooke, V. G., Nonami, A., Ren, T., Sanda, T., Simkin, I., Yuan, J., Antonakos, B., Barys, L., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0429 · Cited by 56
Chargari, C., Leteur, C., Angevin, E., Bashir, T., Schoentjes, B., Arts, J., Janicot, M., Bourhis, J., & Deutsch, E. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.08.011 · Cited by 54 · cited 2×
“…theMDM2-p53 complex from interacting with the proteasome and has progressed to phase I clinical trials for advanced stage or refractory tumors (Chargari et al., 2011; Kojima, Burks, Arts, & Andreeff, 2010; Patel & Player, 2008; Tabernero et al., 2011) (NCT00676910),while HLI98s and related…”
BackgroundZhuang, C., Miao, Z., Wu, Y., Guo, Z., Li, J., Yao, J., Xing, C., Sheng, C., & Zhang, W. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401800k · Cited by 50 · cited 2×
“…nanomolar binding affinities to MDM2 and with one pyrrolidinone exhibiting dual MDM2/MDMX activity (Zhuang et al., 2012) and one pyrrolopyrazole seemingly active against both MDM2 and the NF-κB complex (Zhuang et al., 2014), a different cancer-related pathway (DiDonato, Mercurio, & Karin, 2012).”
BackgroundSmall molecules that bind the Mdm2 RING stabilize and activate p53
Roxburgh, P., Hock, A. K., Dickens, M. P., Mezna, M., Fischer, P. M., & Vousden, K. H. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs092 · Cited by 43 · cited 2×
“…et al., 2010; Patel & Player, 2008; Tabernero et al., 2011) HLI98 5-Deazaflavin Inhibits MDM2 ubiquitin ligase activity (Dickens et al., 2013; Roxburgh et al., 2012; Yang et al., 2005) SP-141 Pyirdo[b]indole MDM2 degradation (Wang et al., 2014) SJ-172550 imidazoline MDMX:p53 antagonist…”
BackgroundKang, M. H., Reynolds, C. P., Kolb, E. A., Gorlick, R., Carol, H., Lock, R., Keir, S. T., Maris, J. M., Wu, J., Lyalin, D., et al. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26064 · Cited by 36 · cited 5×
“Molecule Clinical trial Standalone/combination ClinicalTrials.gov identifier Status Company RG7112 (RO5045337) ▪ Advanced solid tumors ▪ Liposarcomas ▪ Hematological neoplasms ▪ Soft tissue sarcomas ▪ AML ▪ Standalone ▪ Standalone ▪ Standalone ▪ Doxorubicin ▪ Cytarabine ▪ NCT00559533 ▪ NCT01143740 ▪ NCT00623870 ▪ NCT0…”
BackgroundInfluentialPhelps, D., Bondra, K., Seum, S., Chronowski, C., Leasure, J., Kurmasheva, R. T., Middleton, S., Wang, D., Mo, X., & Houghton, P. J. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25465 · Cited by 27
Cited by
Glioblastoma Therapy: Past, Present and Future
Obrador, E., Moreno-Murciano, P., Oriol-Caballo, M., López-Blanch, R., Pineda, B., Gutiérrez-Arroyo, J., Loras, A., Gonzalez-Bonet, L., Martinez-Cadenas, C., Estrela, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052529 · Cited by 271
Multifaceted role for p53 in pancreatic cancer suppression
Mello, S. S., Flowers, B. M., Mazur, P. K., Lee, J. J., Müller, F., Denny, S. K., Ferreira, S., Hanson, K., Kim, S. K., Greenleaf, W. J., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2211937120 · Cited by 55
Kocik, J., Machula, M., Wisniewska, A., Surmiak, E., Holak, T. A., & Skalniak, L. (2019) · Cancers · doi:10.3390/cancers11071014 · Cited by 46
“Since the discovery of the first potent small-molecular inhibitors of HDM2-p53 interactions, numerous chemical scaffolds have been published and tested [31,109].”
BackgroundCDK4 inhibition diminishes p53 activation by MDM2 antagonists
Sriraman, A., Dickmanns, A., Najafova, Z., Johnsen, S. A., & Dobbelstein, M. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0968-0 · Cited by 40
Targeted covalent inhibitors of MDM2 using electrophile-bearing stapled peptides
Charoenpattarapreeda, J., Tan, Y. S., Iegre, J., Walsh, S. J., Fowler, E., Eapen, R. S., Wu, Y., Sore, H. F., Verma, C. S., Itzhaki, L., et al. (2019) · Chemical Communications · doi:10.1039/c9cc04022f · Cited by 35
Metadata
- Authors
- Nguyen, D., Liao, W., Zeng, S. X., & Lu, H.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2017-10
- Volume
- 178
- Pages
- 92-108
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2601051489
- Cited by
- 79
- References
- 87
- FWCI
- 3.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.